von Willebrand factor (VWF) freshly released from endothelial cells is normally cleaved by the ADAMTS-13 metalloprotease to prevent the direct release of these ultra-large (UL) and hyper-reactive multimers into plasma. The balance of ULVWF proteolysis may be regulated by the amount of ULVWF released and the processing capacity of ADAMTS-13. The former associates with the size of ULVWF storage pool, sensitivity of vascular endothelial cells to stimulation, and the type of agonists, whereas the latter associates with the activity of ADAMTS-13. These parameters may vary significantly among individuals. We have determined the variations of ADAMTS-13 activity in 68 normal individuals by a flow-based assay and a static assay using ULVWF strings and recombinant VWF A2 domain as substrates, respectively. We found that the levels of ADAMTS-13 activity required to cleave the platelet-decorated ULVWF strings under flow is significantly higher than that of static assays. Normal plasma diluted to 25% significantly reduced its ability to cleave ULVWF strings under flow, whereas 2% plasma retained 48% enzyme activity in static assay. ADAMTS-13 activity varied from 33 to 100% among individuals and the variations were greater at shorter incubations of plasma with the substrate. Furthermore, the production of ULVWF from endothelial cells also varied among individuals. These results suggest that the commonly used static assays may underestimate the ADAMTS-13 activity required to cleave newly released ULVWF. They also demonstrated that the proteolysis of ULVWF may vary significantly among individuals, potentially contributing to the individual's vulnerability to thrombosis so that measurement of ADAMTS-13 may serve as a marker for TTP and other thrombotic diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1538-7836.2004.00830.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-Nucleotide Polymorphisms in Thrombotic Thrombocytopenic Purpura: A Genetic Predisposition to Immune Thrombotic Thrombocytopenic Purpura.
Cureus
December 2024
Hematology and Oncology, University of Texas MD Anderson Cancer Center, Galveston, USA.
There are two main classifications for thrombotic thrombocytopenic purpura (TTP): immune and hereditary. The majority of TTP cases are immune in nature and are due to inhibitor autoantibodies against ADAMTS13. Hereditary TTP is caused by biallelic pathogenic variants in the ADAMTS13 gene.
View Article and Find Full Text PDFReal-World Retrospective Audit on the Use of the TechnoClone TECHNOSCREEN ADAMTS-13 Assay in the Diagnostic Process for Thrombotic Thrombocytopenic Purpura at LabPlus, New Zealand.
Int J Lab Hematol
December 2024
LabPLUS, Auckland City Hospital, Auckland, New Zealand.
Introduction: The TECHNOSCREEN ADAMTS-13 assay (ADSC) is a new lateral flow test which is simple and quick to perform, with a high negative predictive value (NPV); it may improve the diagnostic workflow for TTP. LabPlus in Auckland, New Zealand, performs all ADAMTS13 tests in the Auckland and Northland regions. The ADSC was used at LabPlus between 2022 and 2023 as part of a protocol where results of 0 IU/mL and 0.
View Article and Find Full Text PDFA Unique Presentation of Atypical Hemolytic Uremic Syndrome With Unilateral Blindness and Ischemic Stroke: A Case Report.
Cureus
November 2024
Department of Medicine, Dr. Baba Saheb Ambedkar Medical College and Hospital, New Delhi, IND.
Article Synopsis
- The report discusses a unique case of atypical hemolytic uremic syndrome (aHUS) that involved multiple body systems, notably resulting in unilateral blindness and a stroke.
- This condition is rarely reported with unilateral blindness, typically linked to central retinal artery obstruction (CRAO).
- This is the first documented instance of aHUS leading to unilateral blindness due to severe (grade four) hypertensive retinopathy.
A novel automated chemiluminescent enzyme immunoassay for ADAMTS-13 activity enables accompanying measurements of the inhibitory autoantibodies.
J Thromb Haemost
December 2024
Department of Hematology, Nara Medical University, Kashihara, Japan; Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan. Electronic address:
Article Synopsis
- TTP is a serious condition linked to low activity of the ADAMTS-13 enzyme, with traditional testing methods being slow and labor-intensive.
- A new automated chemiluminescent enzyme immunoassay (CLEIA) has been developed, which is sensitive and quick, allowing results in just 17 minutes.
- The CLEIA showed excellent agreement with conventional assays in accurately measuring ADAMTS-13 activity and detecting inhibitory antibodies, making it a reliable option for diagnosing and monitoring TTP in hospitals.
Mechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura.
Res Pract Thromb Haemost
October 2024
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Article Synopsis
- Antibody-mediated inhibition of ADAMTS-13, a protein critical for blood clotting, leads to immune thrombotic thrombocytopenic purpura (iTTP), but the impact of multiple antibodies on this process is not fully understood.
- The study examines how different antibodies interact with ADAMTS-13 and finds that while both stimulatory and inhibitory antibodies can bind simultaneously, the inhibition prevails when both are present.
- Results suggest that these antibodies modify ADAMTS-13's catalytic activity through allosteric changes, indicating potential pathways for developing new diagnostic and therapeutic strategies for managing iTTP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!